Side-by-side comparison of AI visibility scores, market position, and capabilities
Solventum (SOLV) reported ~$8.2B revenue in FY2024. Medical technology company spun off from 3M in 2024, providing wound care, oral care, healthcare IT, and purification products. HQ: Maplewood, MN.
Solventum Corporation is a global medical technology company spun off from 3M Company in April 2024, combining 3M's Health Care segment into an independent publicly traded entity. The company operates four business segments: MedSurg (wound management, surgical solutions), Dental Solutions (3M/Solventum brand dental products), Health Information Systems (clinical documentation and coding software), and Purification & Filtration (membrane filtration for pharmaceuticals and food/beverage). The spinoff created a focused MedTech company with $8+ billion in revenue and operations in over 70 countries.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.